Nuvation Bio Inc - Ordinary Shares - Class A

NYSE:NUVB  
11.06
+0.09 (+0.82%)
4:00:00 PM EDT: $11.08 +0.02 (+0.18%)
Earnings Announcements

Nuvation Bio Expects To Submit Up To Five Additional Investigational NDA With U.S. FDA By 2026

Published: 03/11/2021 23:15 GMT
Nuvation Bio Inc - Ordinary Shares - Class A (NUVB) - Nuvation Bio Inc - Expect to Submit Up to Five Additional Investigational NDA With the U.S. FDA by 2026.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.07

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.08

More details on our Analysts Page.